Trump Administration Announces Agreement to Purchase Eli Lilly COVID-19 Investigational Therapeutic

The Department of Health and Human Services and Department of Defense announced an agreement with Eli Lilly and Company to purchase the first doses of the company’s COVID-19 investigational antibody therapeutic bamlanivimab, also known as LY-CoV555.